跳至主要内容
临床试验/NL-OMON41899
NL-OMON41899已完成不适用

Immunological profiling of hilar and mediastinal lymph nodes in lung cancer patients - Immunological profiling of lymph nodes in NSCLC

Vrije Universiteit Medisch Centrum0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • * Be willing and able to provide written informed consent for the study.
  • * Be 18 years of age or older on the day of signing informed consent.
  • * A (suspected) diagnosis of NSCLC.
  • * For the exploration and validation part TNM stage cTxN1-2Mx.
  • * For the qualification part TNM stage cT1-2aN0M0 and planned for SABR
  • * At least one lymph node with a minimal short axis diameter of 10 mm.
  • * Eligible to undergo an EBUS procedure according to the treating physician
  • and international guidelines.
  • * Able to undergo an EBUS procedure according to institutional guidelines.

排除标准

  • * Active infection requiring systemic therapy.
  • * A diagnosis of immunodeficiency or is receiving systemic steroid
  • therapy or any other form of immunosuppressive therapy within 7 days prior
  • to the first dose of trial treatment.
  • * A known additional malignancy that is progressing or requires active treatment.
  • Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in
  • situ cervical cancer that has undergone potentially curative therapy.
  • * Major surgery or blood transfusions in the past 3 months.

研究者

相似试验